Zanubrutinib for treating Waldenström's macroglobulinaemia [ID1427]
In development [GID-TA10705] Expected publication date: 17 August 2022
Search results
525 results
-
-
Imlifidase for preventing kidney transplant rejection in people with chronic kidney disease [ID1672]
In development [GID-TA10552] Expected publication date: 13 July 2022
-
Ovarian cancer: identifying and managing familial and genetic risk
In development [GID-NG10225] Expected publication date: 13 March 2024
-
Vitamin B12 deficiency, including pernicious anaemia: diagnosis and management
In development [GID-NG10176] Expected publication date: 01 November 2023
-
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]
In development [GID-TA10822] Expected publication date: TBC
-
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]
In development [GID-TA10428] Expected publication date: 20 July 2022
-
Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer [ID3857]
In development [GID-TA10749] Expected publication date: TBC
-
Sacituzumab govitecan for treating unresectable locally advanced or metastatic triple-negative breast cancer after 2 or more therapies [ID3942]
In development [GID-TA10829] Expected publication date: 17 August 2022
-
Zanubrutinib for treating Waldenström's macroglobulinaemia [ID1427]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 26 May 2022.
-
Asthma: diagnosis, monitoring and chronic asthma management
In development [GID-NG10186] Expected publication date: 15 November 2023
-
Setmelanotide for treating obesity caused by LEPR or POMC deficiency [ID3764]
In development [GID-HST10034] Expected publication date: 20 July 2022
-
Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies [ID3950]
In development [GID-TA10849] Expected publication date: 19 July 2023
-
Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids [ID3842]
In development [GID-TA10734] Expected publication date: 22 June 2022
-
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation (CDF review of TA578) [ID3885]
In development [GID-TA10894] Expected publication date: 27 June 2022
-
Otitis media with effusion in under 12s
In development [GID-NG10193] Expected publication date: 28 September 2023
-
Pembrolizumab with lenvatinib for previously treated advanced, metastatic or recurrent endometrial cancer [ID3811]
In development [GID-TA10692] Expected publication date: 04 January 2023
-
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (Review of TA619) [ID3779]
In development [GID-TA10901] Expected publication date: 23 November 2022
-
Lu vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]
In development [GID-TA10730] Expected publication date: 23 November 2022
-
Pembrolizumab in combination with chemotherapy for neoadjuvant treatment of triple negative breast cancer [ID1500]
In development [GID-TA10399] Expected publication date: 23 November 2022
-
Eflornithine for maintenance treatment of high-risk neuroblastoma after 1 therapy in people up to 21 years [ID4060]
In development [GID-TA10990] Expected publication date: TBC
-
Intrapartum care for healthy women and babies (update)
In development [GID-NG10174] Expected publication date: 16 August 2023
-
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer [ID3920 ]
In development [GID-TA10802] Expected publication date: TBC
-
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907 ]
In development [GID-TA10784] Expected publication date: TBC
-
Nivolumab with chemotherapy for neoadjuvant treatment of early non-small-cell lung cancer [ID3757]
In development [GID-TA10632] Expected publication date: TBC
-
Urinary tract infection in under 16s: diagnosis and management
In development [GID-NG10259] Expected publication date: 27 July 2022
-
Vadadustat for treating anaemia in people with chronic kidney disease [ID3821]
In development [GID-TA10877] Expected publication date: TBC
-
Rimegepant for treating or preventing migraine [ID1539]
In development [GID-TA10839] Expected publication date: 01 March 2023
-
Haemochromatosis
In development [GID-NG10287] Expected publication date: 02 October 2024
-
Advocacy services for adults with health and social care needs
In development [GID-NG10156] Expected publication date: 09 November 2022
-
Finerenone for treating chronic kidney disease in people with type 2 diabetes [ID3773]
In development [GID-TA10820] Expected publication date: 14 September 2022
-
Filgotinib for treating moderately to severely active ulcerative colitis [ID3736]
In development [GID-TA10600] Expected publication date: 08 June 2022
-
Diabetic foot problems: prevention and management (update)
In development [GID-NG10285] Expected publication date: 18 January 2023
-
Finerenone for treating chronic kidney disease in people with type 2 diabetes [ID3773]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 6 June 2022.
-
Mosunetuzumab for treating relapsed or refractory follicular lymphoma [ID3931]
In development [GID-TA10816] Expected publication date: 25 January 2023
-
Oleogel-S10 for treating skin wounds associated with epidermolysis bullosa ID1505
In development [GID-TA10654] Expected publication date: TBC
-
Romosozumab for treating severe osteoporosis [ID3936]
In development [GID-TA10828] Expected publication date: 25 May 2022
-
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer [ID3971]
In development [GID-TA10860] Expected publication date: TBC
-
Diroximel fumarate for treating relapsing-remitting multiple sclerosis [ID1673]
In development [GID-TA10714] Expected publication date: 08 June 2022
-
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency [ID3791]
In development [GID-HST10052] Expected publication date: 29 March 2023
-
Ibrutinib for treating Waldenstrom's macroglobulinaemia (CDF Review of TA491) [ID3778]
In development [GID-TA10827] Expected publication date: 08 June 2022
-
Targeted-release budesonide for treating IgA nephropathy ID1434
In development [GID-TA11028] Expected publication date: TBC
-
Type 2 diabetes in adults: management (medicines update)
In development [GID-NG10336] Expected publication date: TBC
-
Natalizumab for treating highly active relapsing-remitting multiple sclerosis [ID4020]
In development [GID-TA11056] Expected publication date: TBC
-
Lumasiran for treating primary hyperoxaluria type 1 [ID3765]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 13 June 2022.
-
Preterm labour and birth
In development [GID-NG10245] Expected publication date: 23 June 2022
-
Beremagene geperpavec for treating dystrophic epidermolysis bullosa in children, young people and adults [ID3959]
In development [GID-TA10868] Expected publication date: TBC
-
Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667]
In development [GID-TA10567] Expected publication date: 18 October 2023
-
Venetoclax for treating chronic lymphocytic leukaemia (CDF review of TA487) [ID3886]
In development [GID-TA10890] Expected publication date: 15 June 2022
-
Pembrolizumab for adjuvant treatment of resected stage 2 melanoma with high risk of recurrence [ID3908 ]
In development [GID-TA10786] Expected publication date: TBC
-
Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]
In development [GID-TAG423] Expected publication date: TBC